

Roisin M Connolly

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7207746/publications.pdf>

Version: 2024-02-01

51
papers

2,400
citations

304701

22
h-index

214788

47
g-index

52
all docs

52
docs citations

52
times ranked

4070
citing authors

#	ARTICLE	IF	CITATIONS
1	Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2+ Breast Tumor Microenvironment. <i>Cancer Immunology Research</i> , 2022, 10, 656-669.	3.4	26
2	Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation. <i>Npj Breast Cancer</i> , 2022, 8, 53.	5.2	11
3	A randomized intervention involving family to improve communication in breast cancer care. <i>Npj Breast Cancer</i> , 2021, 7, 14.	5.2	23
4	Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2021, 125, 28-37.	6.4	62
5	Invasive breast Cancer treatment in Tanzania: landscape assessment to prepare for implementation of standardized treatment guidelines. <i>BMC Cancer</i> , 2021, 21, 527.	2.6	7
6	Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844). <i>Clinical Cancer Research</i> , 2021, 27, 5828-5837.	7.0	18
7	HDAC inhibitors induce LIFR expression and promote a dormancy phenotype in breast cancer. <i>Oncogene</i> , 2021, 40, 5314-5326.	5.9	20
8	Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2247-2256.	1.6	22
9	Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers. , 2021, 9, e002473.		33
10	E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group. <i>Journal of Clinical Oncology</i> , 2021, 39, 3171-3181.	1.6	54
11	Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes. <i>Clinical Breast Cancer</i> , 2021, , .	2.4	6
12	Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. <i>Clinical Breast Cancer</i> , 2020, 20, 145-151.e2.	2.4	21
13	Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis. <i>Clinical Cancer Research</i> , 2020, 26, 2704-2710.	7.0	21
14	Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study. <i>Clinical Cancer Research</i> , 2020, 26, 5329-5337.	7.0	6
15	The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial. <i>Clinical Cancer Research</i> , 2020, 26, 3024-3034.	7.0	22
16	Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 141.	4.1	35
17	Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach. <i>JCO Oncology Practice</i> , 2020, 16, 665-674.	2.9	44
18	Best Foot Forward: Neoadjuvant Systemic Therapy as Standard of Care in Triple-Negative and HER2-Positive Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e1-e16.	3.8	9

#	ARTICLE	IF	CITATIONS
19	Trial in progress: A phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer.. Journal of Clinical Oncology, 2020, 38, TPS1102-TPS1102.	1.6	7
20	Sharing in care: engaging care partners in the care and communication of breast cancer patients. Breast Cancer Research and Treatment, 2019, 177, 127-136.	2.5	17
21	Reply to E. HindiÃ© et al. Journal of Clinical Oncology, 2019, 37, 2092-2093.	1.6	1
22	Pathogenic Germline Variants in Patients With Metastatic Breast Cancer. JAMA Oncology, 2019, 5, 1506.	7.1	10
23	TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. Journal of Clinical Oncology, 2019, 37, 714-722.	1.6	36
24	TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer and Brain Metastases. Journal of Clinical Oncology, 2019, 37, 1081-1089.	1.6	251
25	Racial disparities in the rate of cardiotoxicity of HER2â€“targeted therapies among women with early breast cancer. Cancer, 2018, 124, 1904-1911.	4.1	59
26	E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. Npj Breast Cancer, 2018, 4, 1.	5.2	84
27	Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008. Breast Cancer Research and Treatment, 2018, 167, 107-116.	2.5	14
28	2568 Pembrolizumab for patients with leptomeningeal disease from advanced solid tumors. Journal of Clinical and Translational Science, 2018, 2, 44-45.	0.6	0
29	Optimizing HER2-Directed Therapy in Early-Stage Breast Cancer. Current Breast Cancer Reports, 2018, 10, 262-273.	1.0	1
30	Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs. Cancer Immunology Research, 2018, 6, 1561-1577.	3.4	151
31	A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial. Breast Cancer Research and Treatment, 2018, 171, 121-129.	2.5	17
32	TBCRC026: Phase II clinical trial assessing the correlation of standardized uptake value (SUV) on positron emission tomography (PET) with pathological complete response (pCR) to pertuzumab and trastuzumab in patients with primary operable HER2-positive breast cancer.. Journal of Clinical Oncology, 2018, 36, 511-511.	1.6	4
33	Whole-Exome Sequencing of Metaplastic Breast Carcinoma Indicates Monoclonality with Associated Ductal Carcinoma Component. Clinical Cancer Research, 2017, 23, 4875-4884.	7.0	35
34	Entinostat: a promising treatment option for patients with advanced breast cancer. Future Oncology, 2017, 13, 1137-1148.	2.4	94
35	Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. Clinical Cancer Research, 2017, 23, 2691-2701.	7.0	106
36	Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer. Clinical Cancer Research, 2017, 23, 379-386.	7.0	50

#	ARTICLE	IF	CITATIONS
37	Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 4390-4397.	1.6	51
38	FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies. <i>Oncologist</i> , 2016, 21, 931-939.	3.7	174
39	Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2016, 76, 2013-2024.	0.9	40
40	A Clinicopathologic Analysis of 45 Patients With Metaplastic Breast Carcinoma. <i>American Journal of Clinical Pathology</i> , 2016, 145, 365-372.	0.7	72
41	TBCRC 008: Early Change in ¹⁸ F-FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2-Negative Primary Operable Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 31-37.	5.0	61
42	Pertuzumab and its accelerated approval: evolving treatment paradigms and new challenges in the management of HER2-positive breast cancer. <i>Oncology</i> , 2014, 28, 186-94, 196.	0.5	15
43	Molecular Pathways: Current Role and Future Directions of the Retinoic Acid Pathway in Cancer Prevention and Treatment. <i>Clinical Cancer Research</i> , 2013, 19, 1651-1659.	7.0	175
44	Current approaches for neoadjuvant chemotherapy in breast cancer. <i>European Journal of Pharmacology</i> , 2013, 717, 58-66.	3.5	19
45	Epigenetics as a Therapeutic Target in Breast Cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2012, 17, 191-204.	2.7	105
46	Use of androgen deprivation therapy in prostate cancer: indications and prevalence. <i>Asian Journal of Andrology</i> , 2012, 14, 177-186.	1.6	44
47	Early change in 18-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) to predict response to preoperative systemic therapy (PST) in HER2-negative primary operable breast cancer: Translational breast cancer research consortium (TBCRC008).. <i>Journal of Clinical Oncology</i> , 2012, 30, 10509-10509.	1.6	3
48	Pharmacogenetics of Aromatase Inhibitors: Present Understanding and Looking to the Future. <i>Current Breast Cancer Reports</i> , 2010, 2, 138-145.	1.0	0
49	A multidisciplinary approach to neoadjuvant therapy for primary operable breast cancer. Challenges and opportunities. <i>Oncology</i> , 2010, 24, 135-43.	0.5	5
50	High-Dose Chemotherapy plus Stem Cell Transplantation in Advanced Germ Cell Cancer: A Review. <i>European Urology</i> , 2009, 56, 57-64.	1.9	5
51	Early discontinuation of tamoxifen. <i>Cancer</i> , 2007, 109, 832-839.	4.1	254